Yuanjun Shi

A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH ₁ Antagonist) in the Treatment of Major Depression

Brendon Binneman, Douglas E. Feltner, Sheela Kolluri et al. · American Journal of Psychiatry · 2008 · 250 citations

Pharmacy, Pharmacotherapy, Psychiatry +16

Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer

Robert Dreicer, David B. MacLean, Ajit Suri et al. · Clinical Cancer Research · 2014 · 40 citations

Medicine, Pharmacology, Pharmacotherapy +17

Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).

Robert Dreicer, Stéphane Oudard, Eleni Efstathiou et al. · Journal of Clinical Oncology · 2014 · 35 citations

Medicine, Oncology, Pharmacology +12

A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy.

Robert Dreicer, David B. Agus, Joaquim Bellmunt et al. · Journal of Clinical Oncology · 2012 · 10 citations

Medicine, Oncology, Pharmacology +16